Re­silience part­ners with the Cal­i­for­nia In­sti­tute for Re­gen­er­a­tive Med­i­cine to help cell ther­a­py star­tups

As Re­silience keeps up the mo­men­tum post-Se­ries D, the bio­man­u­fac­tur­er has reeled in an­oth­er part­ner­ship, this time in the Gold­en State.

The com­pa­ny an­nounced that it has been named by the Cal­i­for­nia In­sti­tute for Re­gen­er­a­tive Med­i­cine (CIRM) as one of its ini­tial in­dus­try re­source part­ners with­in its in­dus­try al­liance pro­gram (IAP).

The deal will have Re­silience sup­port trans­la­tion­al and clin­i­cal phase grant ap­pli­ca­tions, in­clud­ing TRAN, CLIN1 and CLIN2 grants, for cell ther­a­py pro­grams. The deal al­so has the po­ten­tial to ex­pand to oth­er modal­i­ties such as gene ther­a­pies and bi­o­log­ics in the fu­ture. Re­silience will pro­vide project con­sul­ta­tion that could aid CIRM ap­pli­cants in draft­ing man­u­fac­tur­ing plans and bud­gets for their ap­pli­ca­tions to the pro­gram.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER